Cytokinetics (NASDAQ:CYTK) CEO Sells $606,525.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the company’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $80.87, for a total value of $606,525.00. Following the sale, the chief executive officer owned 377,820 shares of the company’s stock, valued at approximately $30,554,303.40. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Performance

CYTK opened at $80.42 on Friday. The firm has a market cap of $10.01 billion, a P/E ratio of -11.76 and a beta of 0.42. The business has a 50 day moving average price of $78.74 and a 200 day moving average price of $70.34. Cytokinetics, Incorporated has a twelve month low of $32.89 and a twelve month high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) EPS for the quarter, meeting analysts’ consensus estimates of ($1.67). The firm had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. The company’s revenue for the quarter was up 1112.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.36) EPS. As a group, analysts anticipate that Cytokinetics, Incorporated will post -6.2 earnings per share for the current fiscal year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: UK regulatory and reimbursement progress: The Medicines and Healthcare products Regulatory Agency authorized MYQORZO across the United Kingdom for eligible adults with symptomatic obstructive hypertrophic cardiomyopathy. NICE also recommended the treatment for use in England and Wales, potentially expanding access to approximately 6,600 NHS patients. Commercial availability is expected later this year. Cytokinetics wins UK approval, NICE backing for heart disease drug
• Positive Sentiment: Supportive clinical data: The approval was supported by the phase 3 SEQUOIA-HCM trial, in which aficamten produced a statistically significant improvement in peak oxygen uptake versus placebo. The UK authorization and NICE recommendation strengthen the drug’s potential as a future revenue driver for Cytokinetics. Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO and Positive Guidance from NICE
• Neutral Sentiment: Earnings expectations: Analysts expect Cytokinetics to potentially exceed estimates in its upcoming second-quarter report. However, the company remains unprofitable, and its prior quarter included a loss of $1.67 per share despite revenue substantially exceeding expectations. Cytokinetics Expected to Beat Earnings Estimates
• Negative Sentiment: Executive selling adds a sentiment overhang: EVP Andrew Callos sold 14,000 shares worth approximately $1.12 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but it follows a broader pattern of insider selling and no reported insider purchases in recent months. SEC Form 4 filing

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CYTK. JPMorgan Chase & Co. increased their target price on Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Citigroup started coverage on Cytokinetics in a report on Monday, May 18th. They set a “buy” rating and a $99.00 price target for the company. Stifel Nicolaus increased their price objective on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $102.00 target price on shares of Cytokinetics in a research report on Wednesday, June 17th. Finally, Mizuho upped their target price on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cytokinetics currently has a consensus rating of “Moderate Buy” and an average price target of $99.90.

Institutional Trading of Cytokinetics

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Cytokinetics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock worth $765,538,000 after purchasing an additional 191,336 shares during the last quarter. Royce & Associates LP increased its holdings in Cytokinetics by 44.3% during the 4th quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company’s stock valued at $9,177,000 after purchasing an additional 44,343 shares in the last quarter. Norges Bank bought a new position in Cytokinetics in the 4th quarter valued at $51,281,000. GW&K Investment Management LLC raised its position in Cytokinetics by 161.5% in the 4th quarter. GW&K Investment Management LLC now owns 472,363 shares of the biopharmaceutical company’s stock valued at $30,015,000 after purchasing an additional 291,693 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Cytokinetics by 8.0% in the fourth quarter. Fisher Asset Management LLC now owns 822,885 shares of the biopharmaceutical company’s stock worth $52,286,000 after purchasing an additional 61,298 shares in the last quarter.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.